- •Preface to the First Edition
- •Preface to the Second Edition
- •Contents
- •Diagnostic Challenges
- •Expert Centers
- •Patient Organizations
- •Clinical Trials
- •Research in Orphan Lung Diseases
- •Orphan Drugs
- •Orphanet
- •Empowerment of Patients
- •Conclusions
- •References
- •Introduction
- •Challenges to Overcome in Order to Undertake Quality Clinical Research
- •Lack of Reliable Data on Prevalence
- •Small Number of Patients
- •Identifying Causation/Disease Pathogenesis
- •Disease Complexity
- •Lack of Access to a Correct Diagnosis
- •Delay in Diagnosis
- •Challenges But Not Negativity
- •Some Success Stories
- •The Means to Overcome the Challenges of Clinical Research: Get Bigger Numbers of Well-Characterized Patients
- •The Importance of Patient Organizations
- •National and International Networks
- •End Points for Trials: Getting Them Right When Numbers Are Small and Change Is Modest
- •Orphan Drug Development
- •Importance of Referral Centers
- •Looking at the Future
- •The Arguments for Progress
- •Concluding Remarks
- •References
- •3: Chronic Bronchiolitis in Adults
- •Introduction
- •Cellular Bronchiolitis
- •Follicular Bronchiolitis
- •Respiratory Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •Diagnosis
- •Chest Imaging Studies
- •Pulmonary Function Testing
- •Lung Biopsy
- •Mineral Dusts
- •Organic Dusts
- •Volatile Flavoring Agents
- •Infectious Causes of Bronchiolitis
- •Idiopathic Forms of Bronchiolitis
- •Connective Tissue Diseases
- •Organ Transplantation
- •Hematopoietic Stem Cell Transplantation
- •Drug-Induced Bronchiolitis
- •Treatment
- •Constrictive Bronchiolitis
- •Follicular Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •References
- •Background and Epidemiology
- •Pathophysiology
- •Host Characteristics
- •Clinical Manifestations
- •Symptoms
- •Laboratory Evaluation
- •Skin Testing
- •Serum Precipitins
- •Eosinophil Count
- •Total Serum Immunoglobulin E Levels
- •Recombinant Antigens
- •Radiographic Imaging
- •Pulmonary Function Testing
- •Histology
- •Diagnostic Criteria
- •Historical Diagnostic Criteria
- •Rosenberg and Patterson Diagnostic Criteria
- •ISHAM Diagnostic Criteria
- •Cystic Fibrosis Foundation Diagnostic Criteria
- •General Diagnostic Recommendations
- •Allergic Aspergillus Sinusitis (AAS)
- •Natural History
- •Treatment
- •Corticosteroids
- •Antifungal Therapy
- •Monoclonal Antibodies
- •Monitoring for Treatment Response
- •Conclusions
- •References
- •5: Orphan Tracheopathies
- •Introduction
- •Anatomical Considerations
- •Clinical Presentation
- •Etiological Considerations
- •Idiopathic Subglottic Stenosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Introduction and Clinical Presentation
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheomalacia
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchomegaly
- •Introduction
- •Clinical Features
- •Pathophysiology
- •Pulmonary Function Studies
- •Imaging Studies
- •Treatment
- •Tracheopathies Associated with Systemic Diseases
- •Relapsing Polychondritis
- •Introduction
- •Clinical Features
- •Laboratory Findings
- •Pulmonary Function and Imaging Studies
- •Treatment
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchial Amyloidosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Sarcoidosis
- •Introduction
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Orphan Tracheopathies: Conclusions
- •References
- •6: Amyloidosis and the Lungs and Airways
- •Introduction
- •Diagnosis and Evaluation of Amyloidosis
- •Systemic AA Amyloidosis
- •Systemic AL Amyloidosis
- •Amyloidosis Localised to the Respiratory Tract
- •Laryngeal Amyloidosis
- •Tracheobronchial Amyloidosis
- •Parenchymal Pulmonary Amyloidosis
- •Pulmonary Amyloidosis Associated with Sjögren’s Disease
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Genetic Predisposition
- •Immune Dysregulation
- •Epidemiology
- •Incidence and Prevalence
- •Triggering Factors
- •Clinical Manifestations
- •General Symptoms
- •Pulmonary Manifestations
- •Ear, Nose, and Throat (ENT) Manifestations
- •Neurological Manifestations
- •Skin Manifestations
- •Cardiac Manifestations
- •Gastrointestinal Involvement
- •Renal Manifestations
- •Ophthalmological Manifestations
- •Complementary Investigations
- •Diagnosis
- •Diagnostic Criteria
- •Prognosis and Outcomes
- •Phenotypes According to the ANCA Status
- •Treatment
- •Therapeutic Strategies
- •Remission Induction
- •Maintenance Therapy
- •Other Treatments
- •Prevention of AEs
- •Conclusions
- •References
- •8: Granulomatosis with Polyangiitis
- •A Brief Historical Overview
- •Epidemiology
- •Pathogenesis
- •Clinical Manifestations
- •Constitutional Symptoms
- •Ear, Nose, and Throat (ENT) Manifestations
- •Pulmonary Manifestations
- •Kidney and Urological Manifestations
- •Kidney Manifestations
- •Urological Manifestations
- •Neurological Manifestations
- •Peripheral Nervous System (PNS) Manifestations
- •Central Nervous System (CNS) Manifestations
- •Spinal Cord and Cranial Nerve Involvement
- •Skin and Oral Mucosal Manifestations
- •Eye Manifestations
- •Cardiac Involvement
- •Gastrointestinal Manifestations
- •Gynecological and Obstetric Manifestations
- •Venous Thrombosis and Other Vascular Events
- •Other Manifestations
- •Pediatric GPA
- •Diagnosis
- •Diagnostic Approach
- •Laboratory Investigations
- •Biology
- •Immunology
- •Pathology
- •Treatment
- •Glucocorticoids
- •Cyclophosphamide
- •Rituximab
- •Other Current Induction Approaches
- •Other Treatments in GPA
- •Intravenous Immunoglobulins
- •Plasma Exchange
- •CTLA4-Ig (Abatacept)
- •Cotrimoxazole
- •Other Agents
- •Principles of Treatment for Relapsing and Refractory GPA
- •Outcomes and Prognostic Factors
- •Survival and Causes of Deaths
- •Relapse
- •Damage and Disease Burden on Quality of Life
- •Conclusions
- •References
- •9: Alveolar Hemorrhage
- •Introduction
- •Clinical Presentation
- •Diagnosis (Table 9.1, Fig. 9.3)
- •Pulmonary Capillaritis
- •Histology (Fig. 9.4)
- •Etiologies
- •ANCA-Associated Small Vessel Vasculitis: Granulomatosis with Polyangiitis (GPA)
- •ANCA-Associated Small Vessel Vasculitis: Microscopic Polyangiitis
- •Isolated Pulmonary Capillaritis
- •Systemic Lupus Erythematosus
- •Antiphospholipid Antibody Syndrome
- •Anti-Basement Membrane Antibody Disease (Goodpasture Syndrome)
- •Lung Allograft Rejection
- •Others
- •Bland Pulmonary Hemorrhage (Fig. 9.5)
- •Histology
- •Etiologies
- •Idiopathic Pulmonary Hemosiderosis
- •Drugs and Medications
- •Coagulopathy
- •Valvular Heart Disease and Left Ventricular Dysfunction
- •Other
- •Histology
- •Etiologies
- •Hematopoietic Stem Cell Transplantation (HSCT)
- •Cocaine Inhalation
- •Acute Exacerbation of Interstitial Lung Disease
- •Acute Interstitial Pneumonia
- •Acute Respiratory Distress Syndrome
- •Miscellaneous Causes
- •Etiologies
- •Pulmonary Capillary Hemangiomatosis
- •Treatment
- •Conclusions
- •References
- •Takayasu Arteritis
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Clinical Features
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Prognosis
- •Behçet’s Disease
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Diagnostic Criteria
- •Clinical Features
- •Pulmonary Artery Aneurysm
- •Pulmonary Artery Thrombosis
- •Pulmonary Parenchymal Involvement
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Treatment of PAA
- •Treatment of PAT
- •Prognosis
- •References
- •Introduction
- •Portopulmonary Hypertension (PoPH)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •PoPH Treatment
- •Hepatopulmonary Syndrome (HPS)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •HPS Treatment
- •Conclusion
- •References
- •12: Systemic Sclerosis and the Lung
- •Introduction
- •Risk factors for SSc-ILD
- •Genetic Associations
- •Clinical Presentation of SSc-ILD
- •Pulmonary Function Tests (PFTs)
- •Imaging
- •Management
- •References
- •13: Rheumatoid Arthritis and the Lungs
- •Introduction
- •Epidemiology
- •Risk Factors for ILD (Table 13.3)
- •Pathogenesis
- •Clinical Features and Diagnosis
- •Treatments
- •Prognosis
- •Epidemiology
- •Risk Factors
- •Clinical Features, Diagnosis, and Outcome
- •Subtypes or RA-AD
- •Obliterative Bronchiolitis
- •Bronchiectasis
- •COPD
- •Cricoarytenoid Involvement
- •Pleural Disease
- •Conclusion
- •References
- •Introduction
- •Systemic Lupus Erythematosus
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pleural Disease
- •Shrinking Lung Syndrome
- •Thrombotic Manifestations
- •Interstitial Lung Disease
- •Other Pulmonary Manifestations
- •Prognosis
- •Sjögren’s Syndrome
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Airway Disorders
- •Lymphoproliferative Disease
- •Interstitial Lung Disease
- •Prognosis
- •Mixed Connective Tissue Disease
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pulmonary Hypertension
- •Interstitial Lung Disease
- •Prognosis
- •Myositis
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations and Treatments
- •Interstitial Lung Disease
- •Respiratory Muscle Weakness
- •Other Pulmonary Manifestations
- •Prognosis
- •Other Therapeutic Options in CTD-ILD
- •Lung Transplantation
- •Conclusion
- •References
- •Introduction
- •Diagnostic Criteria
- •Controversies in the Diagnostic Criteria
- •Typical Clinical Features
- •Disease Progression and Prognosis
- •Summary
- •References
- •Introduction
- •Histiocytes and Dendritic Cells
- •Introduction
- •Cellular and Molecular Pathogenesis
- •Pathology
- •Clinical Presentation
- •Treatment and Prognosis
- •Erdheim-Chester Disease
- •Epidemiology
- •Cellular and Molecular Pathogenesis
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Chest Studies
- •Cardiovascular Imaging
- •CNS Imaging
- •Bone Radiography
- •Other Imaging Findings and Considerations
- •Disease Monitoring
- •Pathology
- •Management/Treatment
- •Prognosis
- •Rosai-Dorfman Destombes Disease
- •Epidemiology
- •Etiology/Pathophysiology
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Management/Treatment
- •Prognosis
- •Conclusions
- •Diagnostic Criteria for Primary Histiocytic Disorders of the Lung
- •References
- •17: Eosinophilic Pneumonia
- •Introduction
- •Eosinophil Biology
- •Physiologic and Immunologic Role of Eosinophils
- •Release of Mediators
- •Targeting the Eosinophil Cell Lineage
- •Historical Perspective
- •Clinical Presentation
- •Pathology
- •Diagnosis
- •Eosinophilic Lung Disease of Undetermined Cause
- •Idiopathic Chronic Eosinophilic Pneumonia
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Treatment
- •Outcome and Perspectives
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Lung Biopsy
- •Treatment and Prognosis
- •Eosinophilic Granulomatosis with Polyangiitis
- •History and Nomenclature
- •Pathology
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Pathogenesis
- •Diagnosis
- •Treatment and Prognosis
- •Long-Term Outcome
- •Hypereosinophilic Syndrome
- •Pathogenesis
- •Clinical and Imaging Features
- •Laboratory Studies
- •Treatment and Prognosis
- •Eosinophilic Pneumonias of Parasitic Origin
- •Tropical Eosinophilia [191]
- •Ascaris Pneumonia
- •Eosinophilic Pneumonia in Larva Migrans Syndrome
- •Strongyloides Stercoralis Infection
- •Eosinophilic Pneumonias in Other Infections
- •Allergic Bronchopulmonary Aspergillosis
- •Pathogenesis
- •Diagnostic Criteria
- •Biology
- •Imaging
- •Treatment
- •Bronchocentric Granulomatosis
- •Miscellaneous Lung Diseases with Associated Eosinophilia
- •References
- •Introduction
- •Pulmonary Langerhans’ Cell Histiocytosis
- •Epidemiology
- •Pathogenesis
- •Diagnosis
- •Clinical Features
- •Extrathoracic Lesions
- •Pulmonary Function Tests
- •Chest Radiography
- •High-Resolution Computed Tomography (HRCT)
- •Bronchoscopy and Bronchoalveolar Lavage (BAL)
- •Lung Biopsy
- •Pathology
- •Treatment
- •Course and Prognosis
- •Case Report I
- •Introduction
- •Epidemiology
- •Clinical Features
- •Histopathological Findings
- •Radiologic Findings
- •Prognosis and Therapy
- •Desquamative Interstitial Pneumonia
- •Epidemiologic and Clinical Features
- •Histopathological Findings
- •Radiological Findings
- •Prognosis and Therapy
- •Conclusion
- •References
- •19: Lymphangioleiomyomatosis
- •Introduction
- •Pathogenesis
- •Presentation
- •Prognosis
- •Management
- •General Measures
- •Parenchymal Lung Disease
- •Pleural Disease
- •Renal Angiomyolipoma
- •Abdominopelvic Lymphatic Disease
- •Pregnancy
- •Tuberous Sclerosis
- •Drug Treatment
- •Bronchodilators
- •mTOR Inhibitors
- •Anti-Oestrogen Therapy
- •Experimental Therapies
- •Interventions for Advanced Disease
- •Oxygen Therapy
- •Pulmonary Hypertension
- •References
- •20: Diffuse Cystic Lung Disease
- •Introduction
- •Lymphangioleiomyomatosis
- •Pathogenesis
- •Pathologic and Radiographic Characteristics
- •Diagnostic Approach
- •Pulmonary Langerhans Cell Histiocytosis (PLCH)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Birt-Hogg-Dubé Syndrome (BHD)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Lymphoproliferative Disorders
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Amyloidosis
- •Light Chain Deposition Disease (LCDD)
- •Conclusion
- •References
- •Introduction
- •Lymphatic Development
- •Clinical Presentation of Lymphatic Disorders
- •Approaches to Diagnosis and Management of Congenital Lymphatic Anomalies
- •Generalized Lymphatic Anomaly
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Course/Prognosis
- •Management
- •Kaposiform Lymphangiomatosis
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Gorham Stout Disease
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Channel-Type LM/Central Conducting LM
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Yellow Nail Syndrome
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Summary
- •References
- •Introduction
- •Historical Note
- •Epidemiology
- •Pathogenesis
- •Surfactant Homeostasis in PAP
- •GM-CSF Signaling Disruption
- •Myeloid Cell Dysfunction
- •GM-CSF Autoantibodies
- •Lymphocytosis
- •Clinical Manifestations
- •Clinical Presentation
- •Secondary Infections
- •Pulmonary Fibrosis
- •Diagnosis
- •Pulmonary Function Testing
- •Radiographic Assessment
- •Bronchoscopy and Bronchoalveolar Lavage
- •Laboratory Studies and Biomarkers
- •GM-CSF Autoantibodies
- •Genetic Testing
- •Lung Pathology
- •Diagnostic Approach to the Patient with PAP
- •Natural History and Prognosis
- •Treatment
- •Whole-Lung Lavage
- •Subcutaneous GM-CSF
- •Inhaled GM-CSF
- •Other Approaches
- •Conclusions and Future Directions
- •References
- •Introduction
- •Epidemiology
- •Gastric Contents
- •Pathobiology of GER/Microaspirate in the Lungs of Patients with IPF
- •GER and the Microbiome
- •Diagnosis
- •Clinical History/Physical Exam
- •Investigations
- •Esophageal Physiology
- •Upper Esophageal Sphincter
- •Esophagus and Peristalsis
- •Lower Esophageal Sphincter and Diaphragm
- •Esophageal pH and Impedance Testing
- •High Resolution Esophageal Manometry
- •Esophagram/Barium Swallow
- •Bronchoalveolar Lavage/Sputum: Biomarkers
- •Treatment
- •Anti-Acid Therapy (PPI/H2 Blocker)
- •GER and Acute Exacerbations of IPF
- •Suggested Approach
- •Summary and Future Directions
- •References
- •Introduction
- •Familial Interstitial Pneumonia
- •Telomere Related Genes
- •Genetic
- •Telomere Length
- •Pulmonary Involvement
- •Interstitial Lung Disease
- •Other Lung Disease
- •Hepatopulmonary Syndrome
- •Emphysema
- •Extrapulmonary Manifestations
- •Mucocutaneous Involvement
- •Hematological Involvement
- •Liver Involvement
- •Other Manifestations
- •Treatment
- •Telomerase Complex Agonists
- •Lung Transplantation
- •Surfactant Pathway
- •Surfactant Protein Genes
- •Pulmonary Involvement
- •Treatment
- •Heritable Forms of Pulmonary Fibrosis with Autoimmune Features
- •TMEM173
- •COPA
- •Pulmonary Alveolar Proteinosis
- •GMCSF Receptor Mutations
- •GATA2
- •MARS
- •Lysinuric Protein Intolerance
- •Lysosomal Diseases
- •Hermansky-Pudlak Syndrome
- •Lysosomal Storage Disorders
- •FAM111B, NDUFAF6, PEPD
- •Conclusion
- •References
- •Introduction
- •Pathophysiology
- •Clinical Presentation
- •Epidemiology
- •Genetic Causes of Bronchiectasis
- •Disorders of Mucociliary Clearance
- •Cystic Fibrosis
- •Primary Ciliary Dyskinesia
- •Other Ciliopathies
- •X-Linked Agammaglobulinemia
- •Chronic Granulomatous Disease and Other Disorders of Neutrophil Function
- •Other Genetic Disorders Predisposing to Bronchiectasis
- •Idiopathic Bronchiectasis
- •Diagnosis of Bronchiectasis
- •Management of Patients with Bronchiectasis
- •Airway Clearance Therapy (ACT)
- •Management of Infections
- •Immune Therapy
- •Surgery
- •Novel Therapies for Managing Cystic Fibrosis
- •Summary
- •References
- •Pulmonary Arteriovenous Malformations
- •Background Pulmonary AVMs
- •Anatomy Pulmonary AVMs
- •Clinical Presentation of Pulmonary AVMs
- •Screening Pulmonary AVMs
- •Treatment Pulmonary AVMs
- •Children with Hereditary Hemorrhagic Telangiectasia
- •Pulmonary Hypertension
- •Pulmonary Hypertension Secondary to Liver Vascular Malformations
- •Pulmonary Arterial Hypertension
- •Background HHT
- •Pathogenesis
- •References
- •27: Pulmonary Alveolar Microlithiasis
- •Introduction
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Management
- •Summary
- •References
- •Introduction
- •Hermansky-Pudlak Syndrome
- •Telomerase-Associated Pulmonary Fibrosis
- •Lysosomal Storage Diseases
- •Lysinuric Protein Intolerance
- •Familial Hypocalciuric Hypercalcemia
- •Surfactant Dysfunction Disorders
- •Concluding Remarks
- •References
- •Introduction
- •Background
- •Image Acquisition
- •Key Features of Fibrosis
- •Ancillary Features of Fibrosis
- •Other Imaging Findings in FLD
- •Probable UIP-IPF
- •Indeterminate
- •Alternative Diagnosis
- •UIP in Other Fibrosing Lung Diseases
- •Pleuroparenchymal Fibroelastosis (PPFE)
- •Combined Pulmonary Fibrosis and Emphysema
- •Chronic Hypersensitivity Pneumonitis
- •Other Fibrosing Lung Diseases
- •Fibrosing Sarcoidosis
- •CTD-ILD and Drug-Induced FLD
- •Complications
- •Prognosis
- •Computer Analysis of CT Imaging
- •The Progressive Fibrotic Phenotype
- •Other Imaging Techniques
- •Conclusion
- •References
- •Introduction
- •Bronchoalveolar Lavage (BAL)
- •Technique
- •Interpretation
- •Transbronchial Biopsy (TBB)
- •Transbronchial Lung Cryobiopsy (TLCB)
- •References
- •Introduction
- •Overview of ILD Diagnosis
- •Clinical Assessment
- •Radiological Assessment
- •Laboratory Assessment
- •Integration of Individual Features
- •Multidisciplinary Discussion
- •Diagnostic Ontology
- •Conclusions
- •References
- •Introduction
- •Idiopathic Pulmonary Fibrosis
- •Chronic Hypersensitivity Pneumonitis
- •Connective Tissue Disease
- •Drug-Induced Lung Diseases
- •Radiation Pneumonitis
- •Asbestosis
- •Hermansky-Pudlak Syndrome
- •Risk Factors for Progression
- •Diagnosis
- •Pharmacological Management
- •Conclusions
- •References
- •Historical Perspective
- •Epidemiology and Etiologies
- •Tobacco Smoking and Male Sex
- •Genetic Predisposition
- •Systemic Diseases
- •Other Etiological Contexts
- •Clinical Manifestations
- •Pulmonary Function and Physiology
- •Imaging
- •Computed Tomography Characteristics and Patterns
- •Thick-Walled Large Cysts
- •Imaging Phenotypes
- •Pitfalls
- •Pathology
- •Diagnosis
- •CPFE Is a Syndrome
- •Biology
- •Complications and Outcome
- •Mortality
- •Pulmonary Hypertension
- •Lung Cancer
- •Acute Exacerbation of Pulmonary Fibrosis
- •Other Comorbidities and Complications
- •Management
- •General Measures and Treatment of Emphysema
- •Treatment of Pulmonary Fibrosis
- •Management of Pulmonary Hypertension
- •References
- •Acute Interstitial Pneumonia (AIP)
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Desquamative Interstitial Pneumonia (DIP)
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •References
- •Organizing Pneumonias
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Imaging
- •Multifocal Form
- •Isolated Nodular Form
- •Other Imaging Patterns
- •Histopathological Diagnosis of OP Pattern
- •Etiological Diagnosis of OP
- •Treatment
- •Clinical Course and Outcome
- •Severe Forms of OP with Respiratory Failure
- •Acute Fibrinous and Organizing Pneumonia
- •Granulomatous Organizing Pneumonia
- •Acute Interstitial Pneumonia
- •Epidemiology
- •Clinical Picture
- •Imaging
- •Histopathology
- •Diagnosis
- •Treatment
- •Outcome
- •References
- •36: Pleuroparenchymal Fibroelastosis
- •Introduction
- •Epidemiology
- •Clinical Manifestations
- •Laboratory Findings
- •Respiratory Function
- •Radiologic Features
- •Pathologic Features
- •Diagnosis
- •Treatment
- •Prognosis
- •Conclusions
- •References
- •Introduction
- •Acute Berylliosis
- •Chronic Beryllium Disease
- •Exposure
- •Epidemiology
- •Immunopathogenesis and Pathology
- •Genetics
- •Clinical Description and Natural History
- •Treatment and Monitoring
- •Indium–Tin Oxide-Lung Disease
- •Hard Metal Lung
- •Flock Worker’s Disease
- •Asbestosis
- •Nanoparticle Induced ILD
- •Flavoring-Induced Lung Disease
- •Silica-Induced Interstitial Lung Disease
- •Chronic Silicosis
- •Acute and Accelerated Silicosis
- •Chronic Obstructive Disease in CMDLD
- •Simple CMDLD
- •Complicated CMDLD
- •Conclusion
- •References
- •38: Unclassifiable Interstitial Lung Disease
- •Introduction
- •Diagnostic Scenarios
- •Epidemiology
- •Clinical Presentation
- •Diagnosis
- •Clinical Features
- •Radiology
- •Laboratory Investigations
- •Pathology
- •Conclusion
- •References
- •39: Lymphoproliferative Lung Disorders
- •Introduction
- •Nodular Lymphoid Hyperplasia
- •Lymphocytic Interstitial Pneumonia (LIP)
- •Follicular Bronchitis/Bronchiolitis
- •Castleman Disease
- •Primary Pulmonary Lymphomas
- •Primary Pulmonary MALT B Cell Lymphoma
- •Pulmonary Plasmacytoma
- •Follicular Lymphoma
- •Lymphomatoid Granulomatosis
- •Primary Pulmonary Hodgkin Lymphoma (PPHL)
- •Treatment
- •References
- •Introduction
- •Late-Onset Pulmonary Complications
- •Bronchiolitis Obliterans (BO)
- •Pathophysiology
- •Diagnosis
- •Management of BOS
- •Post-HSCT Organizing Pneumonia
- •Other Late-Onset NonInfectious Pulmonary Complications (LONIPCs)
- •Conclusion
- •References
- •Introduction
- •Pulmonary Hypertension Associated with Sarcoidosis (Group 5.2)
- •PH Associated with Pulmonary Langerhans Cell Histiocytosis (Group 5.2)
- •PH in Combined Pulmonary Fibrosis and Emphysema (Group 3.3)
- •PH Associated with Lymphangioleiomyomatosis (Group 3)
- •Hereditary Hemorrhagic Telangiectasia (Group 1.2)
- •Pulmonary Veno-Occlusive Disease (Group 1.5)
- •Small Patella Syndrome (Group 1.2)
- •Conclusion
- •References
- •Introduction
- •Epidemiology
- •Timing, Chronology, Delay Time
- •Route of Administration
- •Patterns of Involvement [3, 4]
- •Drugs and Agents Fallen Out of Favor
- •Drug-Induced Noncardiac Pulmonary Edema
- •Drug-Induced Cardiogenic Pulmonary Edema
- •The “Chemotherapy Lung”
- •Drug-Induced/Iatrogenic Alveolar Hemorrhage
- •Drugs
- •Superwarfarin Rodenticides
- •Transfusion Reactions: TACO–TRALI
- •Acute Eosinophilic Pneumonia
- •Acute Granulomatous Interstitial Lung Disease
- •Acute Organizing Pneumonia (OP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), or Acute Fibrinous Organizing Pneumonia (AFOP) Patterns
- •Acute Amiodarone-Induced Pulmonary Toxicity (AIPT)
- •Accelerated Pulmonary Fibrosis
- •Acute Exacerbation of Previously Known (Idiopathic) Pulmonary Fibrosis
- •Anaphylaxis
- •Acute Vasculopathy
- •Drug-Induced/Iatrogenic Airway Emergencies
- •Airway Obstruction as a Manifestation of Anaphylaxis
- •Drug-Induced Angioedema
- •Hematoma Around the Upper Airway
- •The “Pill Aspiration Syndrome”
- •Catastrophic Drug-Induced Bronchospasm
- •Peri-operative Emergencies (Table 42.8)
- •Other Rare Presentations
- •Pulmonary Nodules and Masses
- •Pleuroparenchymal Fibroelastosis
- •Late Radiation-Induced Injury
- •Chest Pain
- •Rebound Phenomenon
- •Recall Pneumonitis
- •Thoracic Bezoars: Gossipybomas
- •Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
- •Eye Catchers
- •Conclusion
- •References
- •Cancer Mimics of Organizing Pneumonia
- •Lung Adenocarcinoma/Bronchioloalveolar Carcinoma
- •Primary Pulmonary Lymphoma
- •Cancer Mimics of Interstitial Lung Diseases
- •Lymphangitic Carcinomatosis
- •Epithelioid Hemangio-Endothelioma
- •Lymphomatoid Granulomatosis
- •Cystic Tumors
- •Cavitating Tumors
- •Intrathoracic Pseudotumors
- •Respiratory Papillomatosis
- •Pulmonary Langerhans Cell Histiocytosis
- •References
- •Index
470 |
E. M. de Gussem and M. E. Faughnan |
|
|
effect in patients with HHT and PAH [60–62], though there is limited evidence. Caution is warranted with the use of pulmonary vasodilators since systemic vasodilatation could increase any systemic shunt and worsen heart failure. Sildena l, a phosphodiesterase-5 inhibitor has also been reported to be bene cial in one case of PAH in HHT [63]. Anticoagulation is not absolutely contraindicated in HHT patients, but its use, rather, should be decided on a case-by- case basis.
Background HHT
HHT is an autosomal dominant inherited disorder affecting 1 in 5000–10,000 persons, characterized by the presence of vascular malformations. HHT has also been previously referred to as Osler-Weber-Rendu disease. HHT is characterized by the presence of mucocutaneous telangiectases (Fig. 26.5), recurrent epistaxis, visceral AVMs, and positive family history. These characteristics are the four diagnostic criteria for HHT (Table 26.1). The diagnosis of HHT is de - nite if patients meet ≥3 criteria. The diagnosis is possible if they meet two criteria and the diagnosis of HHT is unlikely if patients meet ≤1 criterion [64].
Patients have recurrent spontaneous epistaxis, with an average age of onset of 12 years. Ninetyve percent of patients have recurrent epistaxis by the age of 40. The average diagnostic delay, between ENT consultation for epistaxis and HHT diagnosis, is approximately 15 years [65]. Mucocutaneous telangiectasia is typically present on the lips, oral cavity, nasal mucosa, and skin of the face and hands. Mucocutaneous telangiectasia increases in number with aging. By the age of 20 years, 55–60% of patients have visible mucocutaneous telangiectasia [66, 67]. Visceral AVMs can be present in the lungs, liver, brain, spine, or rarely other organs. Clinical heterogeneity is the rule, with
Table 26.1 Clinical diagnostic criteria for hereditary hemorrhagic telangiectasia
Mucocutaneous telangiectasia
Frequent recurrent spontaneous epistaxis
Visceral arteriovenous malformations
Affected rst-degree relative
Table 26.2 Genotype-phenotype correlation of organ involvement in patients with hereditary hemorrhagic telangiectasia [6–8]
|
Endoglin mutation |
ACVRL1 mutation |
|
(%) |
(%) |
Pulmonary AVM |
49–76 |
5–44 |
Cerebral VM |
9–22 |
0–4 |
Liver VM |
8–60 |
41–83 |
Gastrointestinal |
60–72 |
51–66 |
telangiectasia |
|
|
AVM arteriovenous malformation, VM vascular malformation
HHT clinical manifestations being often highly variable amongst families and within families. Genotype-phenotype correlations are described above and detailed in Table 26.2. Since epistaxis and mucocutaneous telangiectasia are not always present during childhood or adolescence, HHT cannot always be diagnosed or ruled out based on clinical criteria in younger patients, and therefore genetic testing is often required.
Eightyve percent of patients have a mutation in the Endoglin (ENG) gene on chromosome 9 (HHT-1) [68], or a mutation in the ACVRL-1 gene on chromosome 12 (HHT-2) [69, 70]. Less common mutations for HHT are mutations in the SMAD4 gene on chromosome 18 occurring in 2% of patients and generally associated with an overlapping juvenile polyposis syndrome [5, 71]. Approximately 90% of patients with HHT have a mutation in one of these three genes [4].
Pathogenesis
|
Endoglin and ACVRL1 are surface proteins on endothelial |
|
cells. Endoglin is a coreceptor, enhancing bone morphoge- |
|
netic protein (BMP) 9 and BMP10 ligand binding to the |
|
ACVRL1/BMPR2 receptor on epithelial cells. This binding |
|
activates the SMAD 1/5/8 signaling pathway, which normally |
|
inhibits VEGF signaling. VEGF signaling is important in |
|
angiogenesis. In HHT, because of haploinsuf ciency of the |
|
endoglin or ACVRL1 gene, there is a loss of function of the |
|
endoglin and ACVRL1 receptor expression on cell surfaces. |
|
It is hypothesized that a second hit is required for AVM devel- |
|
opment: for example, infammation and subsequent cytokine |
|
release lead to biallelic loss of endoglin or ACVRL1 gene |
|
expression. Current understanding is that this leads to a loss |
Fig. 26.5 Mucocutaneous telangiectasia on the lips |
of BMP9/10 signaling, driving a corresponding local increase |
26 Pulmonary Vascular Manifestations of Hereditary Hemorrhagic Telangiectasia |
471 |
|
|
in PI3K–AKT–mTOR signaling and an untempered response of VEGF with increased endothelial cell proliferation, which contributes to AVM formation, as recently reviewed [72].
Treatment of persons with HHT with the VEGF inhibitor bevacizumab has shown to decrease the severity of epistaxis and to improve high-output heart failure due to shunting from liver vascular malformations [52], and is recommended for severe and refractory disease [21]. Smaller studies have shown that pazopanib, a tyrosine kinase inhibitor that inhibits the VEGF receptor, reduced the frequency of epistaxis in persons with HHT [73] and reduced blood transfusion requirements in severe bleeders. Several anti-VEGF therapies and other pathway-based therapies are currently being investigated in pre-clinical and clinical trials and offer hope for effective systemic treatment of HHT [74].
References
1.\White RI, Lynch-Nyhan A, Terry P, et al. Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy. Radiology. 1988;169(3):663–9. http://www.ncbi.nlm.nih.gov/ pubmed/3186989. Accessed 16 Aug 2012.
2.\Wong H, Chan R, Klatt R, Faughnan M. Idiopathic pulmonary arteriovenous malformations: clinical and imaging characteristics. Eur Respir J. 2011;38(2):368–75. December 2010:1–27. papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p11.
3.\Gossage JR, Kanj G. Pulmonary arteriovenous malformations a state of the art review. Crit Care Med. 1998;158:643–61.
4.\Prigoda NL, Savas S, Abdalla SA, et al. Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J Med Genet. 2006;43(9):722–8. https://doi.org/10.1136/ jmg.2006.042606.
5.\Gallione CJ, Richards JA, Letteboer TGW, et al. SMAD4 mutations found in unselected HHT patients. J Med Genet. 2006;43(10):793– 7. https://doi.org/10.1136/jmg.2006.041517.
6.\Lesca G, Olivieri C, Burnichon N, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med. 2007;9(1):14–22. https:// doi.org/10.1097/GIM.0b013e31802d8373.
7.\Letteboer TGW, Mager JJ, Snijder RJ, et al. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet. 2006;43(4):371–7. https://doi.org/10.1136/jmg.2005.035451.
8.\Sabba C, Pasculli G, Lenato GM, et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost. 2007;5(6):1149–57. https://doi.org/10.1111/ j.1538-7836.2007.02531.x. JTH02531 [pii].
9.\White I, Mitchell SE, Kaufma L. Angioarchitecture of pulmonary arteriovenous malformations: embolotherapy. Am J Roentgenol.
1983;140(4):681–6. |
|
|
|
|
|
|||
10.\Faughnan |
M, Lui |
YW, Wirth JA, et al. Diffuse pul- |
||||||
monary |
|
|
arteriovenous |
malformations: |
character- |
|||
istics |
|
and |
prognosis. |
Chest. |
2000;117(1):31–8. |
|||
papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p115. |
||||||||
11.\Pierucci |
P, |
Murphy |
J, Henderson |
K, |
Chyun |
D, White |
||
R. New |
de nition and natural history of patients |
with dif- |
||||||
fuse |
pulmonary |
arteriovenous |
malformations: |
twenty- |
||||
seven-year |
experience. |
Chest. |
|
2008;133(3):653–61. |
||||
papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p114. 12.\Cottin V, Plauchu H, Dupuis-Girod S, Cordier J-F. Pulmonary arte-
riovenous malformations in patients with hereditary hemorrhagic
telangiectasia: follow-up and pathophysiologic considerations. J Vasc Interv Radiol. 2007;18(7):938–9. https://doi.org/10.1016/j. jvir.2006.12.741.
13.\Moussouttas M, Fayad P, Rosenblatt M, et al. Pulmonary arteriovenous malformations: cerebral ischemia and neurologic manifestations. Neurology. 2000;55(7):959–64. http://www.ncbi.nlm.nih. gov/pubmed/11061251. Accessed 16 Aug 2012.
14.\Cottin V, Chinet T, Lavolé A, et al. Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients. Medicine (Baltimore). 2007;86(1):1–17. https://doi. org/10.1097/MD.0b013e31802f8da1.
15.\Mathis S, Dupuis-Girod S, Plauchu H, et al. Cerebral abscesses in hereditary haemorrhagic telangiectasia: a clinical and microbiological evaluation. Clin Neurol Neurosurg. 2012;114(3):235–40. https://doi.org/10.1016/j.clineuro.2011.10.036.
16.\Shovlin C, Jackson |
J, Bamford K, et al. Primary determinants |
of ischaemic stroke/brain abscess risks are independent of |
|
severity of pulmonary arteriovenous malformations in heredi- |
|
tary haemorrhagic |
telangiectasia. Thorax. 2008;63(3):259–66. |
papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p95. 17.\Shovlin C, Sodhi V, McCarthy A, Lasjaunias P, Jackson J,
Sheppard M. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber- Rendu syndrome): suggested approach for obstetric services. BJOG. 2008;115(9):1108–15. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&l ist_uids=18518871.
18.\Post MC, van Gent MW, Plokker HW, et al. Pulmonary
arteriovenous |
malformations |
associated |
with |
migraine with aura. Eur Respir |
J. 2009;34(4):882–7. |
||
papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p54. |
|
||
19.\Thenganatt J, Schneiderman J, Hyland RH, Edmeads J, Mandzia JL, Faughnan ME. Migraines linked to intrapulmonary right- to-left shunt. Headache. 2006;46(3):439–43. https://doi. org/10.1111/j.1526-4610.2006.00291.x.
20.\Faughnan M, Palda V, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48(2):73–87. papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p48.
21.\Faughnan ME, Mager JJ, Hetts SW, et al. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020;173(12):989–1001. https://doi.org/10.7326/M20-1443.
22.\Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D, Cordier JF. Pulmonary arteriovenous malformations in patients with
hereditary hemorrhagic telangiectasia. |
Am J Respir Crit |
Care Med. 2004;169(9):994–1000. |
https://doi.org/10.1164/ |
rccm.200310-1441oc. |
|
23.\van Gent MWF, Post MC, Snijder RJ, et al. Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: does it predict the indication for embolotherapy? Chest. 2009;135(5):1288–92. https://doi.org/10.1378/chest.08-1266.
24.\Velthuis S, Buscarini E, Mager JJ, et al. Predicting the size of pulmonary arteriovenous malformations on chest computed tomography: a role for transthoracic contrast echocardiography. Eur Respir J. 2014;44(1):150–9. https://doi.org/10.1183/09031936.00133713.
25.\Zukotynski K, Chan RP, Chow CM, Cohen JH, Faughnan M. Contrast echocardiography grading predicts pulmonary arteriovenous malformations on CT. Chest. 2007;132(1):18–23. http:// chestjournal.chestpubs.org/content/132/1/18.long.
26.\Parra JA, Bueno J, Zarauza J, et al. Graded contrast echocardiography in pulmonary arteriovenous malformations. Eur Respir J. 2010;35(6):1279–85. https://doi.org/10.1183/09031936.00104309.
27.\Wilson W, Taubert KA, Gewitz M, et al. Prevention of |
infec- |
||
tive endocarditis: guidelines |
from the |
American |
Heart |
Association: a guideline from |
the American |
Heart Association |
|
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
472 |
|
|
|
|
|
|
|
|
|
|
|
E. M. de Gussem and M. E. Faughnan |
|||||||
|
|
||||||||||||||||||
Rheumatic Fever, Endocarditis and Kawasaki Disease |
43.\Buonamico P, Suppressa P, Lenato GM, et al. Liver involvement |
||||||||||||||||||
Committee, Council on Cardiovascular Disease in the Young, |
in a large cohort of patients with hereditary hemorrhagic telangi- |
||||||||||||||||||
and the Cou. J Am Dent Assoc. 2008;139(Suppl):3S–24S. |
ectasia: echo-color-Doppler vs multislice computed tomography |
||||||||||||||||||
papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p100. |
study. J Hepatol. 2008;48(5):811–20. https://doi.org/10.1016/j. |
||||||||||||||||||
28.\Letourneau-Guillon L, Faughnan ME, Soulez G, et al. |
jhep.2007.12.022. |
|
|
|
|
|
|
|
|
|
|||||||||
Embolization of pulmonary arteriovenous malformations with |
44.\Buscarini |
E, Danesino C, Olivieri C, Lupinacci G, |
Zambelli |
||||||||||||||||
amplatzer vascular plugs: safety and midterm effectiveness. J Vasc |
A. Liver involvement in hereditary haemorrhagic telangiectasia or |
||||||||||||||||||
Interv |
Radiol. 2010;21(5):649–56. http://www.ncbi.nlm.nih.gov/ |
Rendu-Osler-Weber disease. Dig Liver Dis. 2005;37(9):635–45. |
|||||||||||||||||
pubmed/20346701. Accessed 2 Aug 2012. |
|
https://doi.org/10.1016/j.dld.2005.04.010. |
|
|
|
|
|
||||||||||||
29.\Mager JJ, Overtoom TTC, Blauw H, Lammers JWJ, Westermann |
45.\Goussous |
T, Haynes |
A, |
Najarian |
K, |
Daccarett |
M, |
David |
|||||||||||
CJJ. Embolotherapy of pulmonary arteriovenous malfor- |
S. Hereditary hemorrhagic telangiectasia presenting as high |
||||||||||||||||||
mations: long-term results in 112 patients. J Vasc Interv |
output cardiac failure during pregnancy. Cardiol Res Pract. |
||||||||||||||||||
Radiol. |
|
2004;15(5):451–6. |
http://www.ncbi.nlm.nih.gov/ |
2009;2009:437237. |
|
|
|
|
|
|
|
|
|
||||||
pubmed/15126654. Accessed 16 Aug 2012. |
|
46.\Livneh A, Langevitz P, Morag B, Catania A, Pras M. Functionally |
|||||||||||||||||
30.\Gamondès D, Si-Mohamed S, Cottin V, et al. Vein diameter on |
reversible hepatic arteriovenous stulas during pregnancy in |
||||||||||||||||||
unenhanced multidetector ct predicts reperfusion of pulmonary |
patients |
with |
hereditary |
hemorrhagic |
telangiectasia. |
South |
|||||||||||||
arteriovenous malformation after embolotherapy. Eur Radiol. |
Med |
J. |
1988;81(8):1047–9. |
http://www.ncbi.nlm.nih.gov/ |
|||||||||||||||
2016;26(8):2723–9. https://doi.org/10.1007/s00330-015-4090-8. |
pubmed/3406786. Accessed 10 Jul 2012. |
|
|
|
|
|
|||||||||||||
31.\de Gussem EM, Lausman AY, Beder AJ, et al. Outcomes of preg- |
47.\Faughnan |
M, |
Granton |
J, |
Young |
L. |
The |
|
pulmo- |
||||||||||
nancy in women with hereditary hemorrhagic telangiectasia. |
nary |
vascular |
complications |
of |
hereditary |
|
haemor- |
||||||||||||
Obstet |
Gynecol. |
2014;123(3):514–20. |
https://doi.org/10.1097/ |
rhagic telangiectasia. Eur Respir J. 2009;33(5):1186–94. |
|||||||||||||||
AOG.0000000000000120. |
|
|
|
papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p44. |
|||||||||||||||
32.\Yeomans ER, Gilstrap third LC. Physiologic changes in preg- |
48.\Caselitz M, Bahr MJ, Bleck JS, et al. Sonographic criteria for the |
||||||||||||||||||
nancy and their impact on critical care. Crit Care Med. 2005;33(10 |
diagnosis of hepatic involvement in hereditary hemorrhagic tel- |
||||||||||||||||||
Suppl):S256–8. |
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?c |
angiectasia (HHT). Hepatology. 2003;37(5):1139–46. https://doi. |
|||||||||||||||||
md=Retrieve&db=PubMed&dopt=Citation&list_uids=16215345. |
org/10.1053/jhep.2003.50197. |
|
|
|
|
|
|
|
|||||||||||
33.\ACOG. ACOG committee opinion: contrast in pregnancy. Obstet |
49.\Ginon I, Decullier E, Finet G, et al. Hereditary hemorrhagic telan- |
||||||||||||||||||
Gynecol. 2017;130(4):e210–6. |
|
|
|
giectasia, liver vascular malformations and cardiac consequences. |
|||||||||||||||
34.\Curie A, Lesca G, Cottin V, et al. Long-term follow-up in 12 |
Eur J Intern Med. 2013;24(3):e35–9. https://doi.org/10.1016/j. |
||||||||||||||||||
children with pulmonary arteriovenous malformations: con r- |
ejim.2012.12.013. |
|
|
|
|
|
|
|
|
|
|||||||||
mation |
of |
hereditary hemorrhagic |
telangiectasia in |
all cases. |
50.\Buscarini |
E, Leandro G, Conte D, et al. Natural |
history |
||||||||||||
J Pediatr. |
2007;151(3):299–306. |
https://doi.org/10.1016/j. |
and outcome of hepatic vascular malformations in a large |
||||||||||||||||
jpeds.2007.03.021. |
|
|
|
cohort |
of |
patients with hereditary hemorrhagic telangiecta- |
|||||||||||||
35.\Al-Saleh S, Mei-Zahav M, Faughnan ME, et al. Screening for |
sia. Dig Dis Sci. 2011;56(7):2166–78. https://doi.org/10.1007/ |
||||||||||||||||||
pulmonary and cerebral arteriovenous malformations in chil- |
s10620-011-1585-2. |
|
|
|
|
|
|
|
|
|
|||||||||
dren with hereditary haemorrhagic telangiectasia. Eur Respir J. |
51.\Chavan A, Schumann-Binarsch S, Schmuck B, et al. Emerging |
||||||||||||||||||
2009;34(4):875–81. https://doi.org/10.1183/09031936.00030009. |
role of bevacizumab in management of patients with symptomatic |
||||||||||||||||||
36.\Hosman AE, de Gussem EM, Balemans WAF, et al. Screening |
hepatic involvement in hereditary hemorrhagic telangiectasia. Am J |
||||||||||||||||||
children for pulmonary arteriovenous malformations: evaluation |
Hematol. 2017;92(11):E641–4. https://doi.org/10.1002/ajh.24878. |
||||||||||||||||||
of 18 years of experience. Pediatr Pulmonol. 2017;52(9):1206–11. |
52.\Dupuis-Girod S, Ginon I, Saurin J. Bevacizumab in patients with |
||||||||||||||||||
https://doi.org/10.1002/ppul.23704. |
|
|
|
hereditary hemorrhagic telangiectasia and severe hepatic vascular |
|||||||||||||||
37.\Faughnan ME, Thabet A, Mei-Zahav M, et al. Pulmonary arterio- |
malformations and high cardiac output. JAMA J. 2012;307(9):5– |
||||||||||||||||||
venous malformations in children: outcomes of transcatheter embo- |
12. http://jama.ama-assn.org/content/307/9/948.short. Accessed 6 |
||||||||||||||||||
lotherapy. J Pediatr. 2004;145(6):826–31. https://doi.org/10.1016/j. |
Jul 2012. |
|
|
|
|
|
|
|
|
|
|
|
|||||||
jpeds.2004.08.046. |
|
|
|
53.\Lerut J, Orlando G, Adam R, et al. Liver transplantation for heredi- |
|||||||||||||||
38.\Kilian |
A, Clancy MS, Olitsky S, |
Gossage JR, |
Faughnan |
tary hemorrhagic telangiectasia: report of the European liver trans- |
|||||||||||||||
ME. Screening for pulmonary and brain vascular malformations is |
plant registry. Ann Surg. 2006;244(6):854–62; discussion 862–4. |
||||||||||||||||||
the North American standard of care for patients with hereditary |
https://doi.org/10.1097/01.sla.0000247258.35406.a4. |
|
|
|
|||||||||||||||
hemorrhagic telangiectasia (HHT): a survey of HHT Centers of |
54.\Galiè |
N, |
Hoeper MM, |
Humbert |
M, |
et |
al. |
Guidelines |
|||||||||||
Excellence. Vasc Med (United Kingdom). 2021;26(1):53–5. https:// |
for the |
diagnosis |
and |
treatment |
of |
pulmonary |
|
hyper- |
|||||||||||
doi.org/10.1177/1358863X20974452. |
|
|
tension. |
|
Eur |
Respir |
J. |
|
2009;34(6):1219–63. |
||||||||||
39.\Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS |
papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p56. |
||||||||||||||||||
Guidelines for the diagnosis and treatment of pulmonary |
55.\Buscarini E, Plauchu H, Garcia Tsao G, et al. Liver involve- |
||||||||||||||||||
hypertension. Eur Respir J. 2015;46(4):903–75. https://doi. |
ment in hereditary hemorrhagic telangiectasia: consensus rec- |
||||||||||||||||||
org/10.1183/13993003.01032-2015. |
|
|
|
ommendations. Liver Int. 2006;26(9):1040–6. https://doi. |
|||||||||||||||
40.\Garcia-Tsao G, Korzenik J, Young L, et al. Liver disease in |
org/10.1111/j.1478-3231.2006.01340.x. |
|
|
|
|
|
|
||||||||||||
patients with hereditary hemorrhagic telangiectasia. N Engl J Med. |
56.\Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hyper- |
||||||||||||||||||
2000;343:931–6. |
|
|
|
|
tension in France: results from a national registry. Am J Respir |
||||||||||||||
41.\Buscarini E, Danesino C, Olivieri C, et al. Doppler ultrasonographic |
Crit Care Med. 2006;173(9):1023–30. https://doi.org/10.1164/ |
||||||||||||||||||
grading of hepatic vascular malformations in hereditary hemor- |
rccm.200510-1668OC. |
|
|
|
|
|
|
|
|
|
|||||||||
rhagic telangiectasia—results of extensive screening. Ultraschall |
57.\Sztrymf B, Coulet F, Girerd B, et al. Clinical outcomes of pul- |
||||||||||||||||||
Med. 2004;25(5):348–55. https://doi.org/10.1055/s-2004-813,549. |
monary arterial hypertension in carriers of BMPR2 mutation. |
||||||||||||||||||
42.\Stabile Ianora AA, Memeo M, Cirulli A, Rotondo A. Radiology |
Am J Respir Crit Care Med. 2008;177(12):1377–83. https://doi. |
||||||||||||||||||
hereditary hemorrhagic telangiectasia: multi-detector row |
org/10.1164/rccm.200712-1807OC. |
|
|
|
|
|
|
||||||||||||
helical CT assessment of hepatic involvement 1. Radiology. |
58.\Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and func- |
||||||||||||||||||
2004;230(1):250–9. |
|
|
|
tional analysis |
identi es ALK-1 |
as the predominant |
cause of |
||||||||||||
26 Pulmonary Vascular Manifestations of Hereditary Hemorrhagic Telangiectasia |
473 |
|
|
pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet. 2003;40:865–71.
59.\Trembath R, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med.
2001;345(5):325–34. |
|
|
||
60.\Bonderman |
D, Nowotny |
R, Skoro-Sajer N, Adlbrecht C, |
||
Lang IM. Bosentan therapy for pulmonary arterial hyper- |
||||
tension associated |
with |
hereditary haemorrhagic |
telangiec- |
|
tasia. Eur |
J Clin |
Invest. |
2006;36(Suppl 3):71–2. |
https://doi. |
org/10.1111/j.1365-2362.2006.01683.x.
61.\Chang S, Jang S, Ki C, Kang I, Kim D. Successful bosentan therapy for pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia. Heart Vessels. 2011;26(2):231–4. papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p74.
62.\Abston E, Hon S, Rodriguez-Lopez J, et al. Treatment of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia—a case series and systematic review. Pulm
Pharmacol |
Ther. |
2021;68:102033. https://doi.org/10.1016/j. |
pupt.2021.102033. |
|
|
63.\Chadha D, |
Handa |
A, Kumar A. Pulmonary hypertension in |
a patient with hereditary haemorrhagic telangiectasia. BMJ |
||
Case Rep. |
2013;2013:bcr2012008352. https://doi.org/10.1136/ |
|
bcr-2012-008352. |
|
|
64.\Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91(1):66–7. http://www.ncbi. nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt =Citation&list_uids=10751092.
65.\Latino G, Witterick I, Faughnan ME. Hereditary hemorrhagic telantiectasia: an underdiagnosed disease? [Abstract]. Hematol Rep. 2011;3:A19.
66.\Bayrak-Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A. 2006;140(20):2155–62. http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cita tion&list_uids=16969873.
67.\Bayrak-ToydemirP,McdonaldJ,MarkewitzB,etal.Genotype–pheno- type correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. Am J Med Genet Part A. 2006;140A(5):463– 70. papers://1cf21f29-c39e-4648-9064-a20000afc3c2/Paper/p107.
68.\McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF- beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345–51. https://doi.org/10.1038/ng1294-345.
69.\Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13(2):189–95. http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cita tion&list_uids=8640225.
70.\Letteboer TGW, Zewald RA, Kamping EJ, et al. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients. Hum Genet. 2005;116(1–2):8–16. https://doi.org/10.1007/ s00439-004-1196-5.
71.\Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004;363(9412):852–9. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&l ist_uids=15031030.
72.\Snodgrass RO, Chico TJA, Arthur HM. Hereditary haemorrhagic telangiectasia, an inherited vascular disorder in need of improved evidence-based pharmaceutical interventions. Genes (Basel). 2021;12(2):174. https://doi.org/10.3390/genes12020174.
73.\Faughnan ME, Gossage JR, Chakinala MM, et al. Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis. 2019;22(1):145–55. https://doi.org/10.1007/ s10456-018-9646-1.
74.\Parambil JG, Gossage JR, McCrae KR, et al. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. Angiogenesis. 2022;25(1):87–97. https://doi. org/10.1007/s10456-021-09807-4.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/